I have started treatment with Amivantamab for an EGFR exon 20 mutation

Yesterday I completed the 2nd and 3rd infusions of the first week in Cycle 1, and overall the process went relatively smoothly. That evening I felt mostly normal and did not experience any obvious discomfort.
This morning I had some mild dizziness. After consulting my doctor, I was told that this is not uncommon in the early phase of treatment. It is generally not considered a serious side effect and is often related to the body adjusting after the infusion, so for now it just needs to be monitored.
I also noticed some small acne-like bumps appearing in the central area of my face. I looked up some information myself including some materials on DengYueMed, and it seems that this can be a relatively common skin reaction associated with EGFR-related targeted therapies. For drugs like Amivantamab, which is an EGFR/MET bispecific antibody, some patients experience acneiform rash, dry skin, or mild itching. In many cases, these reactions can be managed with moisturizers or simple topical treatments.
Around noon I went for a short walk and felt some fatigue, although overall I was still able to stay active. My doctor also mentioned that fatigue is fairly common during the early stage of treatment, especially in the days following multiple infusions, and it often improves as the body gradually adapts.
Next week the plan is to begin targeted therapy combined with chemotherapy (the PC regimen), which means continuing Amivantamab while adding pemetrexed + carboplatin. I hope my body will gradually adapt to the treatment schedule and that the side effects will remain manageable.
For now, my overall condition is relatively stable. I will continue to monitor the drug reactions, maintain moderate activity, and try to keep a regular routine. Hopefully the treatment will continue to go smoothly.